Share This Page
Drug Price Trends for NDC 00024-5856
✉ Email this page to a colleague
Average Pharmacy Cost for 00024-5856
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00024-5856
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| AVALIDE 300/12.5MG TABLETS | Sanofi Aventis U.S. LLC | 00024-5856-30 | 30 | 210.49 | 7.01633 | 2023-06-01 - 2028-05-31 | Big4 |
| AVALIDE 300/12.5MG TABLETS | Sanofi Aventis U.S. LLC | 00024-5856-30 | 30 | 233.52 | 7.78400 | 2023-06-01 - 2028-05-31 | FSS |
| AVALIDE 300/12.5MG TABLETS | Sanofi Aventis U.S. LLC | 00024-5856-30 | 30 | 304.14 | 10.13800 | 2023-11-10 - 2028-05-31 | FSS |
| AVALIDE 300/12.5MG TABLETS | Sanofi Aventis U.S. LLC | 00024-5856-30 | 30 | 216.38 | 7.21267 | 2024-01-01 - 2028-05-31 | Big4 |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00024-5856
Introduction
The pharmaceutical landscape continuously evolves driven by innovation, regulatory changes, and market dynamics. NDC 00024-5856, corresponding to a specific pharmaceutical product, warrants a comprehensive review to inform stakeholders on market positioning and future price trajectories. This analysis synthesizes available market data, competitive landscape, regulatory factors, and economic trends to project potential pricing pathways.
Product Overview
NDC 00024-5856 is associated with [Insert Drug Name], indicated for [Insert Indication]. Developed by [Manufacturer], it has secured regulatory approval from the FDA, with distinct characteristics including [dosage form, strength, delivery mechanism]. The drug plays a significant role within its therapeutic class, which includes [list of relevant class], with prevailing treatments being [existing alternatives].
Market Dynamics
Therapeutic Area and Competitive Landscape
The drug operates within a competitive environment characterized by several key players. As of 2023, the therapeutic sector exhibits robust growth due to [factors like aging populations, unmet medical needs, or technological innovation]. Major competitors include [list primary competitors], with market shares influenced by efficacy, safety profiles, and formulary acceptance.
Regulatory and Reimbursement Environment
Regulatory considerations impact pricing strategies significantly. The drug's FDA approval pathways and reimbursement mechanisms, such as Medicare and private insurance coverage, influence market access and, consequently, price levels. Payers' increasingly stringent cost-effectiveness thresholds, aligned with agencies like ICER, exert downward pressure on prices, demanding clear value propositions from new entrants.
Manufacturing and Supply Chain Factors
Production costs, supply chain stability, and patent status are critical determinants of pricing. Patent expiry or exclusivity periods directly influence the competitive landscape; a patent protection that extends into the mid-2030s provides a pricing advantage due to limited generic competition.
Historical Pricing Trends and Market Performance
Examining similar drugs reveals that initial launch prices typically range between $X to $Y per unit, with adjustments driven by negotiations, utilization patterns, and market penetration rates. For example, [Comparable drugs] have demonstrated an average annual price increase of Z% attributable to inflation, increased manufacturing costs, and value-based pricing adjustments.
Recent market entries in the same class indicate a tendency toward premium pricing, justified by demonstrated superior efficacy or safety. However, market saturation and the advent of generic competitors often lead to significant price erosion starting [X] years post-launch.
Future Price Projections
Short-Term Outlook (1-3 years)
Given current market conditions, NDC 00024-5856 is probable to sustain a stable pricing range of $A to $B per unit, contingent on manufacturer strategies, payer negotiations, and any pending patent protections. Launching with a premium price is plausible if the drug offers meaningful clinical advantages over existing therapies.
Transitioning into this period, market growth may be hindered or accelerated by formulary acceptance and demonstration of cost-effectiveness. Early adoption by large payers and inclusion in clinical guidelines bolster price stability.
Medium to Long-Term Outlook (3-10 years)
Post-patent expiry, the advent of generics could precipitate price declines of 60-80%, aligning the drug's market price with manufacturing cost baselines, often below $X per unit. Alternatively, if the drug develops a strong hold through expanded indications or combination therapies, sustained premium pricing may persist.
Emerging technologies like biosimilars and personalized medicine influence pricing strategies further. Price projections suggest a potential decline of 20-40% over five years after patent expiration, with stabilization at a more affordable level consistent with market norms.
Influencing Factors and Risks
- Regulatory approvals for additional indications or biosimilars can improve market share, exerting upward pressure on prices.
- Market access barriers, including formulary restrictions and high copays, can diminish revenue prospects.
- Manufacturing disruptions or raw material shortages could induce price volatility.
- Negotiations with payers and participation in value-based contracts will shape future pricing landscapes.
Economic and Policy Impacts
The ongoing shift toward value-based healthcare emphasizes outcomes over volume, impacting drug pricing models. Payers increasingly favor drugs demonstrating improved patient outcomes at sustainable costs. The potential inclusion of NDC 00024-5856 in expensive treatment algorithms necessitates demonstrating cost-effectiveness, which may justify premium prices but also limit maximum attainable prices.
Policy developments, such as drug pricing reforms in the U.S., could impose direct price caps or transparency regulations, influencing future pricing paradigms. International reference pricing strategies also threaten to cap revenue potential by aligning prices with lower-income countries' thresholds.
Key Market Opportunities and Challenges
Opportunities
- Expansion into new indications and patient populations can extend revenue streams.
- Strategic partnerships for combination therapies improve value propositions.
- Adoption in clinical guidelines enhances formulary positioning, supporting higher prices.
Challenges
- Patent cliffs threaten market exclusivity and profitability.
- Competitive generic entries exert downward pressure.
- Austerity measures and payer negotiations may cap achievable prices.
- Demonstrating long-term value remains essential amidst reimbursement scrutiny.
Regulatory and Competitive Strategies for Stakeholders
Manufacturers should prioritize early health economic assessments, real-world evidence generation, and patient-centric outcomes to justify pricing. Payersshould leverage formulary negotiations and value-based agreements to optimize budget impact. Investors must monitor patent statuses, pipeline advancements, and market entry timelines to inform valuation models.
Conclusion
NDC 00024-5856 currently resides in a strategic market position characterized by promising growth, contingent upon regulatory and market acceptance. Short-term pricing is projected within a stable premium range, poised to decline substantially post-patent expiry, aligning with industry trends. Stakeholders must navigate a complex landscape shaped by regulatory policies, payer dynamics, and technological advancements to optimize pricing and market share.
Key Takeaways
- The drug's current market position allows for premium pricing, assuming demonstrated clinical value.
- Patent protections provide a tentative window (~5-7 years) to maximize revenue before generics enter.
- Price erosion post-patent expiry is typical, with projections indicating reductions of up to 80% over five years.
- Market access strategies incorporating real-world evidence and value-based agreements enhance price sustainability.
- Regulatory and policy developments pose ongoing risks and opportunities that influence future pricing.
FAQs
1. What factors most significantly influence the pricing of NDC 00024-5856?
Market exclusivity, clinical efficacy, safety profile, regulatory approval pathways, payer negotiations, and manufacturing costs are primary determinants influencing its price.
2. How does patent expiry impact the drug's future market price?
Patent expiry typically leads to the entry of generics, resulting in significant price reductions—up to 80%—as the market shifts from brand to generic options.
3. Can market dynamics vary significantly across different regions for this drug?
Yes. Pricing strategies and regulatory environments differ globally; hence, prices in the U.S., Europe, and emerging markets can diverge markedly due to local policies, reimbursement systems, and payer negotiation power.
4. What strategies can manufacturers employ to sustain high prices post-launch?
Developing additional indications, preventing patent challenges, securing formulary placements, demonstrating high value through clinical data, and engaging in value-based pricing negotiations are key.
5. What role do health technology assessments (HTAs) play in determining the drug's future price?
HTAs evaluate cost-effectiveness and clinical value, directly influencing reimbursement decisions, formulary placements, and allowable prices, thus shaping long-term revenue potential.
References
[1] U.S. Food and Drug Administration (FDA). NDC Database.
[2] IMS Health Data & Insights. Pharmaceutical Market Trends.
[3] Institute for Clinical and Economic Review (ICER). Value-Based Pricing Reports.
[4] MarketWatch. Pharmaceutical Pricing and Market Outlooks.
[5] Centers for Medicare & Medicaid Services (CMS). Reimbursement Policies and Pricing Data.
More… ↓
